The ART of loss:: Aβ imaging in the evaluation of Alzheimer's disease and other dementias

Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), are proving valuable in the early and differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic strategies aimed at reducing beta-amyloid (A beta) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in developing agents that allow assessment of A beta burden in vivo. A beta burden as assessed by molecular imaging matches histopathological reports of A beta plaque distribution in aging and dementia and appears more accurate than FDG for the diagnosis of AD. A beta imaging is also a very powerful tool in the differential diagnosis of AD from fronto-temporal dementia (FTD). Although A beta burden as assessed by PET does not correlate with measures of cognitive decline in AD, it does correlate with memory impairment and rate of memory decline in mild cognitive impairment (MCI) and healthy older subjects. Approximately 30% of asymptomatic controls present cortical C-11-PiB retention. These observations suggest that A beta deposition is not part of normal ageing, supporting the hypothesis that A beta deposition occurs well before the onset of symptoms and is likely to represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of A beta deposition in the course of Alzheimer's disease.